When Giants Stumble: UnitedHealth Group, A Buy Opportunity?
Exploring Entry Points Amidst Historically Oversold Conditions
This publication, available to everyone, delves into the fundamental and technical analysis of this giant, which has been punished in recent weeks. The question is: Will this price level last forever? When you read the fundamentals analyzed below, you may find the answer.
Weekly Recap: Latest Publications to Read
Considering the open gaps in the S&P 500, this publication analyzed the last 20 years of data, assessing the current market context and how it compares with previous periods when multiple gaps remained unfilled. If you’re watching the recent gaps in the SPX (and NDX), this is a must read for you.
Check the monthly candle for SPX and the implications for June, considering some short term consolidation. This publication has the support and resistance levels for 40 securities that protects you from premature decisions and help you validate bullish and bearish setups. UNH is included in the stocks studied.
The Fundamental Update for NVDA 0.00%↑ was presented in this publication, it is open for everyone, and it presented the bullish setup in the monthly chart, with powerful fundamentals versus the other companies called the Magnificent Seven. The Weekly Compass included more than 20 technical charts for U.S. indices, very relevant companies like PLTR 0.00%↑ NFLX 0.00%↑ AAPL 0.00%↑ MSFT 0.00%↑, Bitcoin, Gold, Silver and more securities.
Unlock all the content posted on smartreversals.com upgrading your subscription:
This occasional publication, available to everyone, offers a comprehensive analysis of a mega-cap stock that has been severely impacted, much like Boeing, Microsoft, and Netflix in the past. Will the stock remain distressed? I doubt it. This publication presents an example of my fundamental approach combined with technical analysis that you find in the site for 40 companies listed in the S&P500 like LMT, JPM, GOOG, AAPL, AMZN, PLTR, and many more.
The previous publication for everyone included fundamentals and technicals for CRWD 0.00%↑ NOW 0.00%↑ HOOD 0.00%↑ and SNOW 0.00%↑ . My bullish view continues playing out, and it was supported by fundamental and technical analysis:
Let’s begin:
UnitedHealth Group (UNH) stands as a leading global healthcare management company, providing services to individuals in the United States and numerous other countries. The firm is notable for its extensive diversification as a payer, evident across its varied product offerings, wide geographical footprint, and broad range of customer segments. UNH's core operations are structured into several key divisions: UnitedHealthcare, OptumRx, OptumInsight, and OptumHealth.
Inside UNH's Scramble to Reverse Profit Plunge Amidst Leadership Upheaval
UnitedHealth Group is currently navigating a complex gauntlet of leadership changes, severe operational disruptions, and starkly declining profitability—a situation now drawing intense investor scrutiny. The healthcare behemoth, despite its formidable scale and a history of impressive top-line expansion, saw its 2024 financial performance significantly marred. This has raised pressing questions about its near-term trajectory and its fundamental ability to convert burgeoning revenue into sustainable profit growth.
The turmoil ignited with the May 13, 2025, announcement: Andrew Witty stepped down as CEO, precipitating the immediate return of former chief executive (2006-2017) Stephen Hemsley. This abrupt leadership shuffle coincided with UNH's decision to suspend its 2025 financial outlook. Adding to the prevailing uncertainty, the company has deferred its updated 2025 guidance, initially anticipated around July 15th, until its second-quarter results presentation on July 29th.
The financial narrative for 2024 was challenging, standing in contrast to a decade of robust growth. While total revenues climbed to an impressive $400.3 billion (up from $371.6 billion in 2023 and a substantial leap from $157.1 billion in 2015), this expansion failed to reach the bottom line. Net Income plummeted to $14.4 billion, or $15.51 per share, a steep fall from the prior year's $22.4 billion, or $23.86 per share.
This precipitous decline was notably influenced by factors such as the Change Healthcare cyberattack, which alone inflicted costs around $3.1 billion. Consequently, Return on Revenue for 2024 cratered to 3.60% from 6.02% in 2023, and Return on Equity contracted sharply to 15.10% from a strong 25.00% (and historical levels typically ranging between 23-25%). This 2024 downturn amplified an already concerning longer-term trend: a five-year (2019-2024) revenue Compound Annual Growth Rate of Revenue (CAGR) of approximately 11% yielded a meager ~2% EPS CAGR. However, it's important to recognize a counterpoint: Operating Earnings per share, a key indicator of core business strength, have consistently climbed over the decade—from $11.40 in 2015 to $34.75 in 2024. This underlying resilience suggests the recent sharp decline in net income might stem more from specific, albeit significant, charges and acute margin pressures than from a fundamental decay in UNH's operational earning power.
Both of UNH’s major segments felt the strain in 2024. UnitedHealthcare continues to grapple with escalating medical cost trends, particularly within its critical Medicare Advantage business. Meanwhile, Optum, the company's services arm and historically a potent growth engine, saw its 2024 operating margin dip to 6.6% (or 7.2% excluding Change Healthcare impacts), down from 7.0% in 2023.
Under Hemsley's renewed leadership, the immediate agenda will focus on stabilizing operations, overhauling medical trend forecasting, and restoring battered margin credibility. Debt has steadily climbed from $33.8 billion in 2015 to $92.7 billion by year-end 2024, a figure that now alarmingly matches its common equity of $92.7 billion. This underscores an urgent need for meticulous capital management amidst deeply pressured earnings.
The Bottom Line: UnitedHealth Group, a titan of the healthcare industry, is clearly navigating a perfect storm of internal and external pressures. Its formidable scale, diversified operations, and the strategic importance of Optum remain significant long-term assets. However, the substantial earnings reset in 2024, coupled with persistent uncertainties around medical costs and the efficacy of its new (yet familiar) leadership to execute a convincing turnaround, warrants a cautious stance. The July 29th update is thus shaping up to be a critical inflection point for UNH 0.00%↑ .
Technical Analysis:
The price is finding support at a confluent level, including the point of control of the current volume shelf (black arrow) and the top before the COVID crash. On the other hand, the RSI is the most oversold it has been since the Great Financial Crisis, not even reaching such levels during the COVID downturn.
The price is brewing a bounce, even if it's just a dead cat bounce. Mark your calendar for July 29th, when news may be priced in following a very likely recovery. In June, the odds for a bounce to $336 are very high (a 10% bounce). Once that level is reached, the daily and weekly price action (candlesticks and oscillators) must be assessed before considering continuation or rejection.
For this week, a bounce remains in play as long as the price stays above $298.9, with an immediate target at $308.7 (which already acted as resistance today). If $298.9 is breached, $292.1 is the support level that may hold the price and where the bounce thesis for June is put in hold. For more levels to watch, the S/R levels publications update the information for UNH every Friday, for the levels of this week, click here.
Considering the long-term support levels mentioned above, technical analysis suggests risk favors bulls, given the oversold conditions and strong fundamentals already discussed.
For educational content about technical analysis get access to the educational library in the smartreversals.com/education, and before finishing let me ask you a question:
Thank you, and have a good night.
This technical analysis is educational content and not intended to be investment advice.